Rare
lephants
Screener
Toggle theme
Kymera Therapeutics, Inc.
KYMR
·
Healthcare, Drug Manufacturers - General, United States
Analysis
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Equity & Debt
Assets & Liabilities
Asset & Liabilities Breakdown
Balance Sheet
›
Assets & Liabilities
Annual
Quarterly
Compare
←
5Y
10Y
MAX
→
Assets & Liabilities
Chart
Table
Total Liabilities
Total Assets
Cash on Hand
Fiscal Year
Total Liabilities
Total Assets
Cash on Hand
FY2025
$163.1M
$1.74B
$357.0M
Download CSV
